FindTrial
Sign In

Association between dexmedetomidine administration and 28-day mortality in critically ill patients with ventilator-associated pneumonia

Association between dexmedetomidine administration and 28-day mortality in critically ill patients with ventilator-associated pneumonia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600117452
Enrollment
Unknown
Registered
2026-01-23
Start date
2025-08-01
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ventilator-associated pneumonia

Interventions

DEX group:DEX use
Non-DEX group:none

Sponsors

The Second People's Hospital of Liaocheng
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 97 Years

Inclusion criteria

Inclusion criteria: Adult patients (aged >= 18 years) diagnosed with VAP, whose diagnosis was based on the ninth edition (ICD-9) and tenth edition (ICD-10) of the International Classification of Diseases, and both were admitted to the ICU for the first time; ICU stay > 24h.

Exclusion criteria

Exclusion criteria: Patients not admitted to the ICU; Patients who stayed in ICU multiple times; Pregnant patients; Patients with lack of dexmedetomidine information.

Design outcomes

Primary

MeasureTime frame
28-day mortality;—

Secondary

MeasureTime frame
ICU mortality;in-hospital mortality;90-day mortality;365-day mortality;—

Countries

China

Contacts

Public ContactTingting Wang

Department of Intensive Care Unit, The Second People’s Hospital of Liaocheng

wangtingting869079@126.com+86 152 6356 7905

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026